Pontifax (China) IV L.P. is Director & 10% Owner at Keros Therapeutics, Inc. (KROS). They have made 1 open-market trade across 1 company since 2025, most recently 2025-10-15.
CIK 0001726030
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KROS | 155,262 | $1.7M |
Shares reported on the most recent Form 4, priced at the 2020-11-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KROS | SELL | 2025-10-15 | 2025-10-17 | $17.75 | $107.6M | +7.3% | +23.9% | +37.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.